Drug resistance in cancer cells
著者
書誌事項
Drug resistance in cancer cells
Springer, c2009
- : hardback
大学図書館所蔵 件 / 全1件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt - in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition - multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies - its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.
目次
Chapter 1: Drug resistance in cancer cells: a historical perspective (Macus T. Kuo, Houston, TX) or Victor Ling (Toronto, Canada) Chapter 2: Metastasis and drug resistance (Kapil Mehta, Houston, TX) or (Isiah Fidler, Houston, TX) Chapter 3: Apoptosis/autophagy and drug resistance (R.S. Krebel, Ontario, Canada) or (Yasuko Kondo, Houston, TX) Chapter 4: Cytokines and drug resistance (Livio Mallucci, London, UK) Chapter 5: Tissue transglutaminase and drug resistance (KapilMehta, Houston, TX) Chapter 6: Integrin signaling and drug resistance (David Cheresh, San Diego, CA) Chapter 7: Oxidative stress and drug resistance Boldogh, Istvan, UTMB, Galveston, TX) Chapter 8: NF-k B and drug resistance (Bharat B. Aggarwal, Houston, TX) Chapter 9: p53 and chemoresistance (Zahid Siddik, Houston, TX) Chapter 10: Resistance to differentiation therapy (Bulent Ozoplat, Houston, TX) Chapter 11: Assessment of cancer drug resistance by nuclear imaging (Sunil Krishnan, Houston, TX) Chapter 12: Overcoming drug resistance by phytochemicals (Bharat B. Aggarwal. Houston, TX) or (Marion M Chan, Philadelphia, USA)
「Nielsen BookData」 より
